Intelligence Platform

Patents

Browse 34 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12421253

Tetrahydropyridopyrimidine pan-KRas inhibitors

Mirati Therapeutics, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421228

Naphthyridine derivatives as PRC2 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12398154

Azaquinazoline pan-KRas inhibitors

Mirati Therapeutics, Inc. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12383503

Adagrasib solid pharmaceutical compositions

Mirati Therapeutics, Inc. · Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12377101

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12371435

Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12336995

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12286431

Crystalline forms of a KRas G12C inhibitor

Mirati Therapeutics, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280055

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281113

Crystalline forms of a KRas G12C inhibitor

Mirati Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252493

Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer

Mirati Therapeutics, Inc. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12208099

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171765

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128048

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999753

Tetrahydropyridopyrimidine pan-KRas inhibitors

Mirati Therapeutics, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964989

KRas G12D inhibitors

Mirati Therapeutics, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11932633

KRas G12C inhibitors

Mirati Therapeutics, Inc. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890285

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548888

KRas G12C inhibitors

Mirati Therapeutics, Inc. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492351

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485738

Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479551

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453683

KRas G12D inhibitors

Mirati Therapeutics, Inc. · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11267812

KRAS G12C inhibitors

Mirati Therapeutics, Inc. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted